GENI Earnings

GENI reported its earnings on 2026-05-07, showcasing a revenue of 187.95M against an estimate of 168.03M, resulting in a 11.86% surprise. The EPS was -0.21, surpassing the expected -0.09 by -133.33%. The stock experienced a 8.64% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GENI's earnings announcement on 2026-05-07, the stock price moved by 8.64% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GENI's stock price tends to shift by an average of -1.02% in the 10 days leading up to earnings and -3.46% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate GENI's annual revenue to reach 142.03M, while the EPS is projected at 0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GENI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GENI's stock price typically moves by -1.02% in the 10 days before its earnings and -3.46% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.01 and revenue of 142.03M.

The earnings call summary and Q&A session reveal strong financial guidance, optimistic growth expectations, and strategic acquisitions. The reaffirmation of 2026 guidance, Legend's accretive impact, and high revenue growth in key markets are positive indicators. The Q&A section further supports positive sentiment with strong revenue generation from prediction markets and successful product integrations. The company's strategic plan and financial health suggest a positive stock price movement, especially given the small-cap nature of the company, which is likely to react strongly to these developments.